Acadia Pharmaceuticals (ACAD) Tops Q3 EPS by 1c
Acadia Pharmaceuticals Inc. (NYSE: ACAD) reports a Q3 loss of $0.23, 1 cent better than the analyst estimate of ($0.24). Revenue for the quarter was $2.4 million, which compares to the estimate of $2 million.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- UPDATE: NetApp, Inc. (NTAP) Tops Q4 EPS by 3c; Guides Q1 Lower
- AFC Enterprises, Inc. (AFCE) Tops Q1 EPS by 4c; Raises FY12 Comps Outlook
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
